tetano
Editor, Senior Moderator
Immunology
. 2021 Nov 14.
doi: 10.1111/imm.13432. Online ahead of print.
Identifying SARS-CoV-2 "memory" NK cells from COVID-19 convalescent donors for adoptive cell therapy
Lara Herrera[SUP] 1 2 [/SUP], Myriam Martin-Inaraja[SUP] 1 2 [/SUP], Silvia Santos[SUP] 1 2 [/SUP], Marta Inglés-Ferrándiz[SUP] 1 2 [/SUP], Aida Azkarate[SUP] 1 2 [/SUP], Miguel A Perez-Vaquero[SUP] 1 2 [/SUP], Miguel A Vesga[SUP] 1 2 [/SUP], Jose L Vicario[SUP] 3 [/SUP], Bernat Soria[SUP] 4 5 [/SUP], Carlos Solano[SUP] 6 7 [/SUP], Raquel De Paz[SUP] 8 [/SUP], Antonio Marcos[SUP] 8 [/SUP], Cristina Ferreras[SUP] 9 [/SUP], Antonio Perez-Martinez[SUP] 9 10 11 [/SUP], Cristina Eguizabal[SUP] 1 2 [/SUP]
Affiliations
Abstract
COVID-19 disease is the manifestation of Syndrome coronavirus 2 (SARS-CoV-2) infection, which is causing a worldwide pandemic. This disease can lead to multiple and different symptoms, being lymphopenia associated with severity one of the most persistent. Natural Killer cells (NK cells) are part of the innate immune system, being fighting against virus-infected cells one of their key roles. In this study, we determined the phenotype of NK cells after COVID-19 and the main characteristic of SARS-CoV-2 specific-like NK population in the blood of convalescent donors. CD57+ NKG2C+ phenotype in SARS-CoV-2 convalescent donors indicate the presence of "memory"/activated NK cells as it has been shown for Cytomegalovirus infections. Although the existence of this population is donor dependent, its expression may be crucial for the specific response against SARS-CoV-2, so that, it gives us a tool for selecting the best donors to produce off-the-shelf living drug for cell therapy to treat COVID-19 patients under the RELEASE clinical trial (NCT04578210).
Keywords: COVID-19; HLA; KIR; NK cells; cell therapy.
. 2021 Nov 14.
doi: 10.1111/imm.13432. Online ahead of print.
Identifying SARS-CoV-2 "memory" NK cells from COVID-19 convalescent donors for adoptive cell therapy
Lara Herrera[SUP] 1 2 [/SUP], Myriam Martin-Inaraja[SUP] 1 2 [/SUP], Silvia Santos[SUP] 1 2 [/SUP], Marta Inglés-Ferrándiz[SUP] 1 2 [/SUP], Aida Azkarate[SUP] 1 2 [/SUP], Miguel A Perez-Vaquero[SUP] 1 2 [/SUP], Miguel A Vesga[SUP] 1 2 [/SUP], Jose L Vicario[SUP] 3 [/SUP], Bernat Soria[SUP] 4 5 [/SUP], Carlos Solano[SUP] 6 7 [/SUP], Raquel De Paz[SUP] 8 [/SUP], Antonio Marcos[SUP] 8 [/SUP], Cristina Ferreras[SUP] 9 [/SUP], Antonio Perez-Martinez[SUP] 9 10 11 [/SUP], Cristina Eguizabal[SUP] 1 2 [/SUP]
Affiliations
- PMID: 34775592
- DOI: 10.1111/imm.13432
Abstract
COVID-19 disease is the manifestation of Syndrome coronavirus 2 (SARS-CoV-2) infection, which is causing a worldwide pandemic. This disease can lead to multiple and different symptoms, being lymphopenia associated with severity one of the most persistent. Natural Killer cells (NK cells) are part of the innate immune system, being fighting against virus-infected cells one of their key roles. In this study, we determined the phenotype of NK cells after COVID-19 and the main characteristic of SARS-CoV-2 specific-like NK population in the blood of convalescent donors. CD57+ NKG2C+ phenotype in SARS-CoV-2 convalescent donors indicate the presence of "memory"/activated NK cells as it has been shown for Cytomegalovirus infections. Although the existence of this population is donor dependent, its expression may be crucial for the specific response against SARS-CoV-2, so that, it gives us a tool for selecting the best donors to produce off-the-shelf living drug for cell therapy to treat COVID-19 patients under the RELEASE clinical trial (NCT04578210).
Keywords: COVID-19; HLA; KIR; NK cells; cell therapy.